Fund profile

SOSV

San Francisco, United States

Not leading

About

SOSV is a leading venture capital firm dedicated to deep tech investments, particularly in human and planetary health. Founded by Sean O'Sullivan, SOSV manages over $1.5 billion in assets and supports more than 1,000 companies across 60 countries. Some of its most notable investments include Upside Foods, Perfect Day, and Novoloop, which focus on sustainable food and materials innovations. The firm’s main programs are HAX and IndieBio. HAX, located in Shenzhen, San Francisco, and Newark, supports startups in industrial automation, health tech, and manufacturing with pre-seed funding and advanced lab resources. IndieBio, with branches in San Francisco and New York, focuses on life sciences, backing startups in agriculture, food tech, and biopharma. These programs offer investments ranging from $250,000 to $525,000 and provide ongoing support through additional funding rounds. SOSV’s strategy emphasizes hands-on assistance, providing founders with access to extensive lab facilities and a global network of over 1,000 co-investors. This approach has led to a high success rate, with 62% of program graduates raising follow-on funding within a year. The firm also values diversity, with a significant portion of its founders being female and from outside the US. The leadership team includes experienced partners like Cyril Ebersweiler and Duncan Turner, who oversee HAX, and Po Bronson and Pae Wu, who lead IndieBio. SOSV also organizes high-profile events, such as the SOSV Climate Tech Summit, to showcase and support its portfolio companies.

Details

Highlights

$45.4k

Historical average check

$500M

Historical max check

January 2025

Last investment date

2817

Investments

Biotech

Healthtech & Wellness

Hardware. Robotics & IoT

Food & Beverage

CleanTech & Sustainability

Agritech & Farming

Pharma

Software & Apps

Consumer Goods & Electronics

Energy & Utilities

Transportation & Mobility

Advertising & Marketing

Real Estate & Proptech

Other

Funds that also invest in Biotech